{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T17:23:42Z","timestamp":1760981022986},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2006,2,15]],"date-time":"2006-02-15T00:00:00Z","timestamp":1139961600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol"],"published-print":{"date-parts":[[2006,8]]},"DOI":"10.1038\/sj.npp.1301044","type":"journal-article","created":{"date-parts":[[2006,2,15]],"date-time":"2006-02-15T15:47:29Z","timestamp":1140018449000},"page":"1832-1837","source":"Crossref","is-referenced-by-count":16,"title":["Tardive Dyskinesia in Schizophrenia is Associated with Prolactin-Related Sexual Disturbances"],"prefix":"10.1038","volume":"31","author":[{"name":"the SOHO Study Group","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diederik E","family":"Tenback","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter N","family":"van Harten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cees J","family":"Slooff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jim","family":"van Os","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2006,2,15]]},"reference":[{"key":"BF1301044_CR1","first-page":"137","volume":"56","author":"D Aizenberg","year":"1995","unstructured":"Aizenberg D, Zemishlany Z, Dorfman-Etrog P, Weizman A (1995). Sexual dysfunction in male schizophrenic patients. J Clin Psychiatry 56: 137\u2013141.","journal-title":"J Clin Psychiatry"},{"key":"BF1301044_CR2","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1111\/j.1600-0447.1988.tb06405.x","volume":"78","author":"A Aleem","year":"1988","unstructured":"Aleem A, Kulkarni A, Yeragani VK (1988). Dexamethasone suppression test, schizophrenia and movement disorder. Acta Psychiatr Scand 78: 689\u2013694.","journal-title":"Acta Psychiatr Scand"},{"key":"BF1301044_CR3","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/BF00428314","volume":"66","author":"GM Asnis","year":"1979","unstructured":"Asnis GM, Sachar EJ, Langer G, Halpern FS, Fink M (1979). Normal prolactin responses in tardive dyskinesia. Psychopharmacology (Berlin) 66: 247\u2013250.","journal-title":"Psychopharmacology (Berlin)"},{"key":"BF1301044_CR4","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1192\/bjp.171.2.148","volume":"171","author":"MP Caligiuri","year":"1997","unstructured":"Caligiuri MP, Lacro JP, Rockwell E, McAdams LA, Jeste DV (1997). Incidence and risk factors for severe tardive dyskinesia in older patients. Br J Psychiatry 171: 148\u2013153.","journal-title":"Br J Psychiatry"},{"key":"BF1301044_CR5","volume-title":"Statistical Models in Epidemiology","author":"D Clayton","year":"1993","unstructured":"Clayton D, Hills M (1993). Statistical Models in Epidemiology. Oxford Science Publications: Oxford."},{"key":"BF1301044_CR6","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1176\/appi.ajp.161.3.414","volume":"161","author":"CU Correll","year":"2004","unstructured":"Correll CU, Leucht S, Kane JM (2004). Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 161: 414\u2013425.","journal-title":"Am J Psychiatry"},{"key":"BF1301044_CR7","unstructured":"CPMP (1996). ICH Topic E 6 Guideline for Good Clinical Practice. EMEA: London, UK."},{"key":"BF1301044_CR8","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/0006-3223(86)90124-1","volume":"21","author":"JG Csernansky","year":"1986","unstructured":"Csernansky JG, Prosser E, Kaplan J, Mahler E, Berger PA, Hollister LE (1986). Possible associations among plasma prolactin levels, tardive dyskinesia, and paranoia in treated male schizophrenics. Biol Psychiatry 21: 632\u2013642.","journal-title":"Biol Psychiatry"},{"key":"BF1301044_CR9","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1001\/archpsyc.1994.03950080055008","volume":"51","author":"WS Fenton","year":"1994","unstructured":"Fenton WS, Wyatt RJ, McGlashan TH (1994). Risk factors for spontaneous dyskinesia in schizophrenia. Arch Gen Psychiatry 51: 643\u2013650.","journal-title":"Arch Gen Psychiatry"},{"key":"BF1301044_CR10","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1176\/ajp.138.11.1493","volume":"138","author":"WM Glazer","year":"1981","unstructured":"Glazer WM, Moore DC, Bowers Jr MD, Brown WA (1981). Serum prolactin and tardive dyskinesia. Am J Psychiatry 138: 1493\u20131496.","journal-title":"Am J Psychiatry"},{"key":"BF1301044_CR11","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/0022-3999(75)90007-0","volume":"2","author":"BA Gregory","year":"1957","unstructured":"Gregory BA (1957). The menstrual cycle and its disorders in psychiatric patients. I. Review of the literature. J Psychosom Res 2: 61\u201379.","journal-title":"J Psychosom Res"},{"key":"BF1301044_CR12","doi-asserted-by":"publisher","first-page":"314","DOI":"10.4158\/EP.5.6.314","volume":"5","author":"MFA Guay","year":"1999","unstructured":"Guay MFA, Velasquez ME, Perez MJ (1999). Characterization of patients in a medical endocrine-based center for male sexual dysfunction. Endocr Pract 5: 314\u2013321.","journal-title":"Endocr Pract"},{"key":"BF1301044_CR13","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.2165\/00003495-200464200-00003","volume":"64","author":"PM Haddad","year":"2004","unstructured":"Haddad PM, Wieck A (2004). Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 64: 2291\u20132314.","journal-title":"Drugs"},{"issue":"Suppl 1","key":"BF1301044_CR14","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0306-4530(02)00112-9","volume":"28","author":"U Halbreich","year":"2003","unstructured":"Halbreich U, Kinon BJ, Gilmore JA, Kahn LS (2003). Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects. Psychoneuroendocrinology 28(Suppl 1): 53\u201367.","journal-title":"Psychoneuroendocrinology"},{"key":"BF1301044_CR15","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1034\/j.1600-0447.2003.00064.x","volume":"107","author":"JM Haro","year":"2003","unstructured":"Haro JM, Edgell ET, Jones PB, Alonso J, Gavart S, Gregor KJ et al (2003). The European Schizophrenia Outpatient Health Outcomes (SOHO) study: rationale, methods and recruitment. Acta Psychiatr Scand 107: 222\u2013232.","journal-title":"Acta Psychiatr Scand"},{"key":"BF1301044_CR16","first-page":"75","volume":"42","author":"DV Jeste","year":"1981","unstructured":"Jeste DV, Neckers LM, Wagner RL, Wise CD, Staub RA, Rogol A et al (1981). Lymphocyte monoamine oxidase and plasma prolactin and growth hormone in tardive dyskinesia. J Clin Psychiatry 42: 75\u201377.","journal-title":"J Clin Psychiatry"},{"key":"BF1301044_CR17","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1093\/oxfordjournals.aje.a010011","volume":"150","author":"MM Joffe","year":"1999","unstructured":"Joffe MM, Rosenbaum PR (1999). Invited commentary: propensity scores. Am J Epidemiol 150: 327\u2013333.","journal-title":"Am J Epidemiol"},{"key":"BF1301044_CR18","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1124\/jpet.102.035303","volume":"302","author":"S Kapur","year":"2002","unstructured":"Kapur S, Langlois X, Vinken P, Megens AA, De Coster R, Andrews JS (2002). The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats. J Pharmacol Exp Therap 302: 1129\u20131134.","journal-title":"J Pharmacol Exp Therap"},{"key":"BF1301044_CR19","first-page":"355","volume":"36","author":"H Knegtering","year":"1999","unstructured":"Knegtering H, Blijd C, Boks MPM (1999). Sexual dysfunctions and prolactin levels in patients using classical antipsychotics, risperidone or olanzapine. Schizophr Res 36: 355\u2013356.","journal-title":"Schizophr Res"},{"issue":"Suppl 2","key":"BF1301044_CR20","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/S0306-4530(02)00130-0","volume":"28","author":"H Knegtering","year":"2003","unstructured":"Knegtering H, van der Moolen AE, Castelein S, Kluiter H, van den Bosch RJ (2003). What are the effects of antipsychotics on sexual dysfunctions and endocrine functioning? Psychoneuroendocrinology 28(Suppl 2): 109\u2013123.","journal-title":"Psychoneuroendocrinology"},{"key":"BF1301044_CR21","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1176\/appi.ajp.162.5.1010","volume":"162","author":"R Knegtering","year":"2005","unstructured":"Knegtering R, Baselmans P, Castelein S, Bosker F, Bruggeman R, van den Bosch RJ (2005). Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels. Am J Psychiatry 162: 1010\u20131012.","journal-title":"Am J Psychiatry"},{"key":"BF1301044_CR22","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/npp.1994.40","volume":"11","author":"JA Lieberman","year":"1994","unstructured":"Lieberman JA, Alvir J, Geisler S, Ramos-Lorenzi J, Woerner M, Novacenko H et al (1994). Methylphenidate response, psychopathology and tardive dyskinesia as predictors of relapse in schizophrenia. Neuropsychopharmacology 11: 107\u2013118.","journal-title":"Neuropsychopharmacology"},{"key":"BF1301044_CR23","first-page":"1085","volume":"44","author":"AA Luciano","year":"1999","unstructured":"Luciano AA (1999). Clinical presentation of hyperprolactinemia. J Reprod Med 44: 1085\u20131090.","journal-title":"J Reprod Med"},{"key":"BF1301044_CR24","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/BF00177564","volume":"96","author":"P Monteleone","year":"1988","unstructured":"Monteleone P, Maj M, Ariano MG, Iovino M, Fiorenza L, Steardo L (1988). Prolactin response to sodium valproate in schizophrenics with and without tardive dyskinesia. Psychopharmacology (Berlin) 96: 223\u2013226.","journal-title":"Psychopharmacology (Berlin)"},{"key":"BF1301044_CR25","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1136\/bmj.327.7412.423","volume":"327","author":"I Nazareth","year":"2003","unstructured":"Nazareth I, Boynton P, King M (2003). Problems with sexual function in people attending London general practitioners: cross sectional study. BMJ 327: 423.","journal-title":"BMJ"},{"key":"BF1301044_CR26","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.pneurobio.2004.05.001","volume":"73","author":"RG Paredes","year":"2004","unstructured":"Paredes RG, Agmo A (2004). Has dopamine a physiological role in the control of sexual behavior? A critical review of the evidence. Prog Neurobiol 73: 179\u2013226.","journal-title":"Prog Neurobiol"},{"key":"BF1301044_CR27","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1038\/sj.npp.1300766","volume":"30","author":"CM Pariante","year":"2005","unstructured":"Pariante CM, Dazzan P, Danese A, Morgan KD, Brudaglio F, Morgan C et al (2005). Increased pituitary volume in antipsychotic-free and antipsychotic-treated patients of the AEsop First-Onset Psychosis Study. Neuropsychopharmacology 30: 1923\u20131931.","journal-title":"Neuropsychopharmacology"},{"key":"BF1301044_CR28","doi-asserted-by":"publisher","first-page":"757","DOI":"10.7326\/0003-4819-127-8_Part_2-199710151-00064","volume":"127","author":"DB Rubin","year":"1997","unstructured":"Rubin DB (1997). Estimating causal effects from large data sets using propensity scores. Ann Intern Med 127: 757\u2013763.","journal-title":"Ann Intern Med"},{"key":"BF1301044_CR29","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.psychres.2004.01.010","volume":"127","author":"M Segal","year":"2004","unstructured":"Segal M, Avital A, Rojas M, Hausvater N, Sandbank S, Liba D et al (2004). Serum prolactin levels in unmedicated first-episode and recurrent schizophrenia patients: a possible marker for the disease's subtypes. Psychiatry Res 127: 227\u2013235.","journal-title":"Psychiatry Res"},{"key":"BF1301044_CR30","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1176\/jnp.17.2.221","volume":"17","author":"JC Shim","year":"2005","unstructured":"Shim JC, Kim YH, Kelly DL, Lee JG, Conley RR (2005). Tardive dyskinesia predicts prolactin response to buspirone challenge in people with schizophrenia. J Neuropsychiatry Clin Neurosci 17: 221\u2013226.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"BF1301044_CR31","unstructured":"StataCorp. (2005). STATA Statistical Software: Release 9.0. College Station: Texas."},{"key":"BF1301044_CR32","first-page":"337","volume":"18","author":"J Tripodianakis","year":"1983","unstructured":"Tripodianakis J, Markianos M, Garelis E (1983). Neurochemical studies on tardive dyskinesia. I. Urinary homovanillic acid and plasma prolactin. Biol Psychiatry 18: 337\u2013345.","journal-title":"Biol Psychiatry"},{"key":"BF1301044_CR33","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1177\/070674370004500310","volume":"45","author":"P Turrone","year":"2000","unstructured":"Turrone P, Seeman MV, Silvestri S (2000). Estrogen receptor activation and tardive dyskinesia. Can J Psychiatry 45: 288\u2013290.","journal-title":"Can J Psychiatry"},{"key":"BF1301044_CR34","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/j.1600-0447.1997.tb10153.x","volume":"96","author":"J van Os","year":"1997","unstructured":"van Os J, Fahy T, Jones P, Harvey I, Toone B, Murray R (1997). Tardive dyskinesia: who is at risk? Acta Psychiatr Scand 96: 206\u2013216.","journal-title":"Acta Psychiatr Scand"},{"key":"BF1301044_CR35","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1034\/j.1600-0447.2000.101004300.x","volume":"101","author":"J van Os","year":"2000","unstructured":"van Os J, Walsh E, van Horn E, Tattan T, Bale R, Thompson SG (2000). Changes in negative symptoms and the risk of tardive dyskinesia: a longitudinal study. UK700 Group. Acta Psychiatrica Scand 101: 300\u2013306.","journal-title":"Acta Psychiatrica Scand"},{"key":"BF1301044_CR36","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1192\/bjp.168.6.702","volume":"168","author":"O Yuen","year":"1996","unstructured":"Yuen O, Caligiuri MP, Williams R, Dickson RA (1996). Tardive dyskinesia and positive and negative symptoms of schizophrenia. A study using instrumental measures. Br J Psychiatry 168: 702\u2013708.","journal-title":"Br J Psychiatry"}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/1301044.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/1301044","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/1301044.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T06:51:10Z","timestamp":1684219870000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/1301044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,2,15]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2006,8]]}},"alternative-id":["BF1301044"],"URL":"https:\/\/doi.org\/10.1038\/sj.npp.1301044","relation":{},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"type":"print","value":"0893-133X"},{"type":"electronic","value":"1740-634X"}],"subject":[],"published":{"date-parts":[[2006,2,15]]}}}